These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33845354)

  • 1. Transcriptional signatures underlying dynamic phenotypic switching and novel disease biomarkers in a linear cellular model of melanoma progression.
    Pessoa DO; Rius FE; Papaiz DD; Ayub ALP; Morais AS; de Souza CF; da Paixão VF; Setubal JC; Newton-Bishop J; Nsengimana J; Azevedo H; Reis EM; Jasiulionis MG
    Neoplasia; 2021 Apr; 23(4):439-455. PubMed ID: 33845354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene co-expression and histone modification signatures are associated with melanoma progression, epithelial-to-mesenchymal transition, and metastasis.
    Azevedo H; Pessoa GC; de Luna Vitorino FN; Nsengimana J; Newton-Bishop J; Reis EM; da Cunha JPC; Jasiulionis MG
    Clin Epigenetics; 2020 Aug; 12(1):127. PubMed ID: 32831131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mining gene expression signature for the detection of pre-malignant melanocytes and early melanomas with risk for metastasis.
    de Souza CF; Xander P; Monteiro AC; Silva AG; da Silva DC; Mai S; Bernardo V; Lopes JD; Jasiulionis MG
    PLoS One; 2012; 7(9):e44800. PubMed ID: 22984562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide promoter methylation profiling in a cellular model of melanoma progression reveals markers of malignancy and metastasis that predict melanoma survival.
    Rius FE; Papaiz DD; Azevedo HFZ; Ayub ALP; Pessoa DO; Oliveira TF; Loureiro APM; Andrade F; Fujita A; Reis EM; Mason CE; Jasiulionis MG
    Clin Epigenetics; 2022 May; 14(1):68. PubMed ID: 35606887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.
    Toricelli M; Melo FH; Peres GB; Silva DC; Jasiulionis MG
    Mol Cancer; 2013 Mar; 12():22. PubMed ID: 23522389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole transcriptome analysis reveals correlation of long noncoding RNA ZEB1-AS1 with invasive profile in melanoma.
    Siena ÁDD; Plaça JR; Araújo LF; de Barros II; Peronni K; Molfetta G; de Biagi CAO; Espreafico EM; Sousa JF; Silva WA
    Sci Rep; 2019 Aug; 9(1):11350. PubMed ID: 31383874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inducibly decreased MITF levels do not affect proliferation and phenotype switching but reduce differentiation of melanoma cells.
    Vlčková K; Vachtenheim J; Réda J; Horák P; Ondrušová L
    J Cell Mol Med; 2018 Apr; 22(4):2240-2251. PubMed ID: 29369499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype.
    Castro-Pérez E; Rodríguez CI; Mikheil D; Siddique S; McCarthy A; Newton MA; Setaluri V
    Stem Cell Reports; 2019 Jul; 13(1):177-192. PubMed ID: 31231022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression.
    Ryu B; Kim DS; Deluca AM; Alani RM
    PLoS One; 2007 Jul; 2(7):e594. PubMed ID: 17611626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of long noncoding RNA and messenger RNA signatures in melanoma tumorigenesis and metastasis.
    Wang S; Fan W; Wan B; Tu M; Jin F; Liu F; Xu H; Han P
    PLoS One; 2017; 12(2):e0172498. PubMed ID: 28225791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRRX1 silencing is required for metastatic outgrowth in melanoma and is an independent prognostic of reduced survival in patients.
    Ferreres JR; Vinyals A; Campos-Martin R; Espín R; Podlipnik S; Ramos R; Bertran E; Carrera C; Marcoval J; Malvehy J; Fabregat I; Puig S; Fabra À
    Mol Oncol; 2024 Oct; 18(10):2471-2494. PubMed ID: 38978350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative behaviour and phenotype plasticity evolve during melanoma progression.
    Rowling EJ; Miskolczi Z; Nagaraju R; Wilcock DJ; Wang P; Telfer B; Li Y; Lasheras-Otero I; Redondo-Muñoz M; Sharrocks AD; Arozarena I; Wellbrock C
    Pigment Cell Melanoma Res; 2020 Sep; 33(5):695-708. PubMed ID: 32145051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revolutionary multi-omics analysis revealing prognostic signature of thyroid cancer and subsequent in vitro validation of SNAI1 in mediating thyroid cancer progression through EMT.
    Jin X; Fu C; Qi J; Chen C
    Clin Exp Med; 2024 Jun; 24(1):127. PubMed ID: 38869635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.
    Fenouille N; Tichet M; Dufies M; Pottier A; Mogha A; Soo JK; Rocchi S; Mallavialle A; Galibert MD; Khammari A; Lacour JP; Ballotti R; Deckert M; Tartare-Deckert S
    PLoS One; 2012; 7(7):e40378. PubMed ID: 22911700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of prdm1a accelerates melanoma onset and progression.
    Iwanaga R; Truong BT; Hsu JY; Lambert KA; Vyas R; Orlicky D; Shellman YG; Tan AC; Ceol C; Artinger KB
    Mol Carcinog; 2020 Sep; 59(9):1052-1063. PubMed ID: 32562448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genes regulated by DNA methylation are involved in distinct phenotypes during melanoma progression and are prognostic factors for patients.
    Papaiz DD; Rius FE; Ayub ALP; Origassa CS; Gujar H; Pessoa DO; Reis EM; Nsengimana J; Newton-Bishop J; Mason CE; Weisenberger DJ; Liang G; Jasiulionis MG
    Mol Oncol; 2022 May; 16(9):1913-1930. PubMed ID: 35075772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systems analysis identifies miR-29b regulation of invasiveness in melanoma.
    Andrews MC; Cursons J; Hurley DG; Anaka M; Cebon JS; Behren A; Crampin EJ
    Mol Cancer; 2016 Nov; 15(1):72. PubMed ID: 27852308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic reprogramming as a key contributor to melanocyte malignant transformation.
    Molognoni F; Cruz AT; Meliso FM; Morais AS; Souza CF; Xander P; Bischof JM; Costa FF; Soares MB; Liang G; Jones PA; Jasiulionis MG
    Epigenetics; 2011 Apr; 6(4):450-64. PubMed ID: 21343701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation States of Phenotypic Transition of Melanoma Cells Are Revealed by 3D Cell Cultures.
    Fontana F; Sommariva M; Anselmi M; Bianchi F; Limonta P; Gagliano N
    Cells; 2024 Jan; 13(2):. PubMed ID: 38247872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching.
    Lessard L; Liu M; Marzese DM; Wang H; Chong K; Kawas N; Donovan NC; Kiyohara E; Hsu S; Nelson N; Izraely S; Sagi-Assif O; Witz IP; Ma XJ; Luo Y; Hoon DSB
    J Invest Dermatol; 2015 Oct; 135(10):2464-2474. PubMed ID: 26016895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.